Christopher Reis, DO, DABA, DABPM
Director of RBS Pain Management Program
Appointment Line: (573) 332-5636
Board Certified: American Board of Anesthesiology, American Board of Anesthesiology/Pain Medicine
DO: Midwestern University – Chicago College of Osteopathic Medicine, Downers Grove, IL
Internship: Loyola University Medical Center, Maywood, IL
Residency: Loyola University Medical Center, Maywood, IL
Fellowship: Loyola University Medical Center, Maywood, IL
Dr. Reis joined Regional Brain & Spine as a pain management physician in August of 2011. He is dedicated to uncovering the root cause of his patients’ pain and developing a multifaceted care plan to address it. The techniques he uses include spinal cord stimulation, radiofrequency ablation, spine and joint injections and treatment for peripheral nerve conditions. Dr. Reis is excited about the new leading edge regenerative medicine options now available at Regional Brain and Spine. These new offerings are intended for promoting healing and reducing pain when other therapies have failed or are not enough. Dr. Reis is also offering the MILD® procedure for treating lumbar spinal stenosis.
Dr. Reis combines his knowledge and experience with a caring bedside manner in order to provide the best experience and results possible for each patient.
He enjoys challenging cases and has a special interest in advanced therapies to treat cancer pain and complex regional pain syndrome.
Dr. Reis is an active member of several professional associations, including the American Pain Society, American Society of Regional Anesthesia and Pain Medicine, American Society of Anesthesiology, American Medical Association and the American Osteopathic Association.
When he isn’t helping patients, Dr. Reis spends time with his three children. He also enjoys snow skiing.
Online Appointments must be scheduled ahead of time.
Learn more about Targeted Drug Delivery
Dr. Reis participated in the following CBS Health Watch video.
In it he discusses a potential alternative to opioid usage for pain control.
Facebook